Overview

Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections

Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this clinical trial was to determine the time to improvement of the signs and symptoms (eg, dysuria, frequency, urgency, gross hematuria, suprapubic pain, hesitancy, low back pain) of acute, uncomplicated, symptomatic, lower UTIs in women treated with Cipro XR 500 mg once daily for 3 days.
Phase:
Phase 4
Details
Lead Sponsor:
Bayer
Treatments:
Ciprofloxacin